The breakdown of preformed peritoneal advanced glycation end products by intraperitoneal alagebrium

Journal of Korean Medical Science

Volumn 24, Issue SUPPL.1, 2009, Pages

  Lee, Yong Kook ^a   Lee, Joon Yeop ^a   Kim, Jun Seup ^a   Won, Ki Bum ^a   Kang, Hyeok Joo ^a   Jang, Tae Jung ^a   Tak, Woo Taek ^b   Lee, Jeong Ho ^a  

^a Dongguk University   (South Korea)

^b Dr Tak's Renal Clinic   (South Korea)

Author keywords

Advanced glycation end products; Alagebrium; Aminoguanidine; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; GUANIDINE DERIVATIVE;

ANIMAL; ARTICLE; BODY WEIGHT; CELL MEMBRANE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; RAT; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BODY WEIGHT; CELL MEMBRANE; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; IMMUNOHISTOCHEMISTRY; MALE; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 62449320294     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.S1.S189     Document Type: Article

References (23)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
2. Vlassara H. Recent progress on the biologic and clonical significance of advanced glycosylation end-products. J Lab Clin Med 1994; 124: 19-39.
3. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-22.
4. Vlassara H. Serum advanced glycosylation end-products: a new class of uremic toxins? Blood Purif 1994; 12: 54-9.
5. Kennedy L, Baynee JW. Non-enzymatic glycosylation and the chronic compliacations of diabetes. An overview Diabetologia 1984; 26: 93-8.\
6. Brownlee M, Cerami A, VLassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular diseases. Diabetes Metab Rev 1988; 4: 437-51.
7. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, Park MS. Structual and fuctional alterations of the poritoneaum after prolonged exposure to dialysis solutions: role of aminoguanidine. Peri Dial Int 2001; 21: 245-53.
8. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Amionguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-32.
9. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Pro Natl Acad Sci USA 1992; 89: 12043-7.
10. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 2000; 43: 660-4.
11. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan H, Ulrich P. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-8.
12. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4.
13. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, De-Groof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation 2001; 104: 1464-70.
14. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-4.
15. Forbes JM, Yee LT, Thallas V, Markus Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper MF, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-23.
16. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-82.
17. Tak WT, Kim SK, Lee JY, Kang HJ, Kim ES, Lee JH. The suppression of peritoneal advanced glycosylation end product formation by intraperitoneal aminoguanidine. Korean J Nephrol 2006; 25: 23-33.
18. Struijk DG, Krediet RT, Kookmen GC, Hoek FJ, Boechoten EW, Reijden HJ, Arisz L. Functional characteristics of the peritoneal membrane in long-term continous ambulatory peritoneal dialysis. Nephron 1991; 59: 213-20.
19. Tooke JE. Microcirculation and diabetes. Br Med Bull 1989; 45: 206-23.
20. Rippe B. Pathophysiological description of the ultrafiltration changes of the peritoneal membrane during long-term continuous ambulatory peritoneal dialysis. Blood Purif 1994; 12: 211-20.
21. Tsilibary EC, Charonis AS, Reger LA, Dege JE, Furcht LT. The effect of nonenzymatic glycosylation on the binding of the main noncollagenous NC1 domain to the type IV collagen. J Biol Chem 1998; 263: 4302-8.
22. Chraronis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990; 39: 807-14.
23. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1397-407. S194